Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / AZN - Albireo Pharma: De-Risked Small-Cap Biotech Ready For Commercialization

AZN - Albireo Pharma: De-Risked Small-Cap Biotech Ready For Commercialization

AstraZeneca PLC
  • Albireo Pharma is developing its lead product candidate Odevixibat for multiple pediatric liver disease indications.
  • The approval of Odevixibat for Progressive Familial Intrahepatic Cholestasis (PFIC) is expected in the second half of 2021.
  • The company is in great financial shape to begin the commercialization of the Odevixibat and to advance its pipeline for adult liver diseases.
  • The stock offers a de-risked investment opportunity which is hard to find in the current elevated market environment.

For further details see:

Albireo Pharma: De-Risked Small-Cap Biotech Ready For Commercialization
Stock Information
Company Name: AstraZeneca PLC
Stock Symbol: AZN
Market: NYSE
Website: astrazeneca.com
Menu
AZN AZN Quote AZN Short AZN News AZN Articles AZN Message Board
Get AZN Alerts

News, Short Squeeze, Breakout and More Instantly...